

SHIPPED: Between 2-1-59 and 5-23-59, the metal frames and canvas covers of the devices were shipped from Los Angeles, Calif., by Inco Co., and the oscillators for the devices were shipped from Los Angeles, Calif., by Crefan Motors.

LABEL IN PART: "Mar V Lounge, Model Marvlmatic."

ACCOMPANYING LABELING: Pamphlets entitled "Mar V Lounge Can Make You Look and Feel Younger Than You Are!," direction sheets entitled "The Pretorius Rx Lounge," testimonial letters dated 3-2-59 and signed by "A. L. Schram," and a number of guarantee cards.

RESULTS OF INVESTIGATION: The assembled device was an adjustable tubular frame, fitted with canvas to provide a cot-like device. A small electric motor, attached to a cross member of the tubular frame provided vibration to the canvas covered frame.

LIBELED: 7-23-59, Dist. Ariz.

CHARGE: 502(a)—the labeling accompanying the article, when shipped and while held for sale, contained false and misleading representations that the device was an adequate and effective treatment for slenderizing, toning and firming the muscles, trimming hips and thighs, increasing weight, overcoming back ailments, controlling weight, improving posture, overcoming tension, toning and lifting sagging tissues and relieving pain caused by tension, and congestion in the tissues.

DISPOSITION: 9-1-59. Consent—claimed by Martin Pretorius, Phoenix, Ariz., and relabeled.

6031. Nemectrodyn device. (F.D.C. No. 41868. S. No. 11-450 P.)

QUANTITY: 1 device at Birmingham, Mich.

SHIPPED: On an unknown date from Lindau, Germany, by Deutsche Nemectron-Gesellschaft m.b.h.

LABEL IN PART: (Metal tag) "Nemectrodyn."

ACCOMPANYING LABELING: Leaflets entitled "Nemectrodyn Interference—Therapy (Physiotherapy)."

RESULTS OF INVESTIGATION: The device consisted of an electrical apparatus which converted household current into stimulating voltages which were applied to the human body through applicator pads.

LIBELED: 6-23-58, E. Dist. Mich.

CHARGE: 502(a)—when shipped and while held for sale, the labeling which accompanied the article contained false and misleading representations that the article was an adequate and effective treatment for overcoming chronic inflammatory infiltrations, relieving atonic or paralyzed muscles, overcoming ankylosis, producing a beneficial effect on the secretory and excretory glands, overcoming ptosis, hypoperistalsis, subacidity, atony of the intestines, atonic obstipation, stasis of the lymph and venous flow, atony and paresis of the striated muscle, intermittent claudication, Raynaud's disease, neuritis, neuralgia, sciatica, arthritis, rheumatism, salpingo-ovaritis, prostatitis, ulcus ventriculi et duodeni, spastic pain, irritation of the autonomic nerve system, and for providing an analgesic sedative and spasmolytic therapy.

DISPOSITION: 7-30-59. Default—delivered to the Food and Drug Administration.